title: Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.
abstract: BACKGROUND
  There is no standard first line treatment for mantle cell lymphoma.
  
  
  METHODS
  This was a multicenter phase II pilot study of rituximab and modified hyper-fractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (modified R-hyperCVAD) administered every 28 days for four to six cycles followed by rituximab maintenance therapy consisting of four weekly doses every 6 months for 2 years. Unlike traditional hyperCVAD regimens, no methotrexate or cytarabine was administered.
  
  
  RESULTS
  Of 22 patients, the overall response rate was 77% and the complete response rate was 64%. With a median follow-up time of 37 months in surviving patients, the median PFS was 37 months and the median OS was not reached. The achievement of a molecular remission did not correlate with improved outcome. The major toxicity was expected myelosuppression. Two patients died during induction treatment. There were no major adverse effects during maintenance therapy.
  
  
  CONCLUSIONS
  In a multicenter trial, modified R-hyperCVAD was tolerable and effective induction therapy for untreated MCL. Maintenance rituximab appeared to prolong PFS without increasing toxicity.
authors.affiliation: Department of Medicine, University of Wisconsin, Madison, WI, USA. bsk@medicine.wisc.edu
authors.forename: B S
authors.initials: BS
authors.lastname: Kahl
authors.forename: W L
authors.initials: WL
authors.lastname: Longo
authors.forename: J C
authors.initials: JC
authors.lastname: Eickhoff
authors.forename: J
authors.initials: J
authors.lastname: Zehnder
authors.forename: C
authors.initials: C
authors.lastname: Jones
authors.forename: J
authors.initials: J
authors.lastname: Blank
authors.forename: T
authors.initials: T
authors.lastname: McFarland
authors.forename: W
authors.initials: W
authors.lastname: Bottner
authors.forename: H
authors.initials: H
authors.lastname: Rezazedeh
authors.forename: J
authors.initials: J
authors.lastname: Werndli
authors.forename: H H
authors.initials: HH
authors.lastname: Bailey
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012074:Remission Induction; D000069283:Rituximab; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; C004180:dexamethasone 21-phosphate; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide